Interacting effects of naltrexone and OPRM1 and DAT1 variation on the neural response to alcohol cues

Neuropsychopharmacology

Volumn 38, Issue 3, 2013, Pages 414-422

  Schacht, Joseph P ^a   Anton, Raymond F ^a   Voronin, Konstantin E ^a   Randall, Patrick K ^a   Li, Xingbao ^a   Henderson, Scott ^a   Myrick, Hugh ^a,b  

^a MUSC Center for Drug and Alcohol Programs   (United States)

^b RALPH H JOHNSON VA MEDICAL CENTER   (United States)

Author keywords

Alcoholism; functional neuroimaging; opioid antagonist; SNP; VNTR

Indexed keywords

ALCOHOL; DOPAMINE TRANSPORTER; MU OPIATE RECEPTOR; NALTREXONE; PLACEBO;

ADULT; AGED; ALCOHOL ABUSE; ALCOHOLISM; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG RECEPTOR BINDING; FEMALE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GENE DOSAGE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; NERVE POTENTIAL; ORBITAL CORTEX; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REWARD; SINGLE NUCLEOTIDE POLYMORPHISM; VARIABLE NUMBER OF TANDEM REPEAT; VENTROMEDIAL PREFRONTAL CORTEX;

ADULT; ALCOHOL DRINKING; ALCOHOLISM; CUES; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; GENETIC VARIATION; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; NALTREXONE; NARCOTIC ANTAGONISTS; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN BINDING; RECEPTORS, OPIOID, MU; TANDEM REPEAT SEQUENCES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84872485355     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2012.195     Document Type: Article

References (65)

1. Aarts E, Roelofs A, Franke B, Rijpkema M, Fernandez G, Helmich RC et al (2010). Striatal dopamine mediates the interface between motivational and cognitive control in humans: evidence from genetic imaging. Neuropsychopharmacology 35: 1943-1951.
2. American Psychiatric Association (2000). Diagnostic and Statis-tical Manual of Mental Disorders 4th edn, text rev. Author: Washington, DC
3. Anton RF, Drobes DJ, Voronin K, Durazo-Avizu R, Moak D (2004). Naltrexone effects on alcohol consumption in a clinical laboratory paradigm: temporal effects of drinking. Psychophar-macology (Berl) 173: 32-40.
4. Anton RF, Moak DH, Latham PK (1996). The obsessive compulsive drinking scale: A new method of assessing outcome in alcoholism treatment studies. Arch Gen Psychiatry 53: 225-231.
5. Anton RF, Oroszi G, O'Malley S, Couper D, Swift R, Pettinati H et al (2008). An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. Arch Gen Psychiatry 65: 135-144.
6. Anton RF, Voronin KK, Randall PK, Myrick H, Tiffany A (2012). Naltrexone modification of drinking effects in a subacute treatment and bar-lab paradigm: influence of OPRM1 and dopamine transporter (SLC6A3) genes. Alcohol Clin Exp Res (e-pub ahead of print).
7. Barr CS, Chen SA, Schwandt ML, Lindell SG, Sun H, Suomi SJ et al (2010). Suppression of alcohol preference by naltrexone in the rhesus macaque: a critical role of genetic variation at the micro-opioid receptor gene locus. Biol Psychiatry 67: 78-80.
8. Benjamin D, Grant ER, Pohorecky LA (1993). Naltrexone reverses ethanol-induced dopamine release in the nucleus accumbens in awake, freely moving rats. Brain Res 621: 137-140.
9. Boettiger CA, Kelley EA, Mitchell JM, D'Esposito M, Fields HL (2009). Now or later? An fMRI study of the effects of endogenous opioid blockade on a decision-making network. Pharmacol Biochem Behav 93: 291-299.
10. Bond C, LaForge KS, Tian M, Melia D, Zhang S, Borg L et al (1998). Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. Proc Natl Acad Sci U S A 95: 9608-9613.
11. Chamorro AJ, Marcos M, Miron-Canelo JA, Pastor I, Gonzalez-Sarmiento R, Laso FJ (2012). Association of micro-opioid receptor (OPRM1) gene polymorphism with response to naltrexone in alcohol dependence: a systematic review and meta-analysis. AddictBiol 17: 505-512.
12. Coller JK, Cahill S, Edmonds C, Farquharson AL, Longo M, Minniti R et al (2011). OPRM1 A118G genotype fails to predict the effectiveness of naltrexone treatment for alcohol dependence. Pharmacogenet Genomics 21: 902-905.
13. Davidson D, Palfai T, Bird C, Swift R (1999). Effects of naltrexone on alcohol self-administration in heavy drinkers. Alcohol Clin Exp Res 23: 195-203.
14. Dreher J-C, Kohn P, Kolachana B, Weinberger DR, Berman KF (2009). Variation in dopamine genes influences responsivity of the human reward system. Proc Natl Acad Sci U S A 106: 617-622.
15. Drobes DJ, Anton RF, Thomas SE, Voronin K (2003). A clinical laboratory paradigm for evaluating medication effects on alcohol consumption: naltrexone and nalmefene. Neuropsychopharma-cology 28: 755-764.
16. Drobes DJ, Anton RF, Thomas SE, Voronin K (2004). Effects of naltrexone and nalmefene on subjective response to alcohol among non-treatment-seeking alcoholics and social drinkers. Alcohol Clin Exp Res 28: 1362-1370.
17. Filbey FM, Ray L, Smolen A, Claus ED, Audette A, Hutchison KE (2008). Differential neural response to alcohol priming and alcohol taste cues is associated with DRD4 VNTR and OPRM1 genotypes. Alcohol Clin Exp Res 32: 1113-1123.
18. First MB, Spitzer RL, Gibbon M, Williams JBW (2002). Structured Clinical Interview for DSM-IV-TR Axis I Disorders Research Version, Non-patient EditionBiometrics Research, New York State Psychiatric Institute: New York.
19. Forbes EE, Brown SM, Kimak M, Ferrell RE, Manuck SB, Hariri AR (2009). Genetic variation in components of dopamine neuro-transmission impacts ventral striatal reactivity associated with impulsivity. Mol Psychiatry 14: 60-70.
20. Franklin TR, Lohoff FW, Wang Z, Sciortino N, Harper D, Li Y et al (2009). DAT genotype modulates brain and behavioral responses elicited by cigarette cues. Neuropsychopharmacology 34: 717-728.
21. Franklin TR, Wang Z, Li Y, Suh JJ, Goldman M, Lohoff FW et al (2011). Dopamine transporter genotype modulation of neural responses to smoking cues: confirmation in a new cohort. Addict Biol 16: 308-322.
22. Fuke S, Suo S, Takahashi N, Koike H, Sasagawa N, Ishiura S (2001). The VNTR polymorphism of the human dopamine trans-porter (DAT1) gene affects gene expression. Pharmacogenom J 1: 152-156.
23. Gelernter J, Gueorguieva R, Kranzler HR, Zhang H, Cramer J, Rosenheck R et al (2007). Opioid receptor gene (OPRM1, OPRK1, and OPRD1) variants and response to naltrexone treatment for alcohol dependence: results from the VA Cooperative Study. Alcohol Clin Exp Res 31: 555-563.
24. Gonzales RA, Job MO, Doyon WM (2004). The role of mesolimbic dopamine in the development and maintenance of ethanol reinforcement. Pharmacol Ther 103: 121-146.
25. Gonzales RA, Weiss F (1998). Suppression of ethanol-reinforced behavior by naltrexone is associated with attenuation of the ethanol-induced increase in dialysate dopamine levels in the nucleus accumbens. J Neurosci 18: 10663-10671.
26. Heinz A, Goldman D, Jones DW, Palmour R, Hommer D, Gorey JG et al (2000). Genotype influences in vivo dopamine transporter availability in human striatum. Neuropsychopharmacology 22: 133-139.
27. Heinz A, Siessmeier T, Wrase J, Hermann D, Klein S, Grüsser SM et al (2004). Correlation between dopamine D(2) receptors in the ventral striatum and central processing of alcohol cues and craving. Am J Psychiatry 161: 1783-1789.
28. Hutchison KE, Haughey H, Niculescu M, Schacht J, Kaiser A, StitzelJ et al (2008). The incentive salience of alcohol: translating the effects of genetic variant in CNR1. Arch Gen Psychiatry 65: 841-850.
29. Hutchison KE, Wooden A, Swift RM, Smolen A, McGeary J, Adler L et al (2003). Olanzapine reduces craving for alcohol: a DRD4 VNTR polymorphism by pharmacotherapy interaction. Neuro-psychopharmacology 28: 1882-1888.
30. Inoue-Murayama M, Adachi S, Mishima N, Mitani H, Takenaka O, Terao K et al (2002). Variation of variable number of tandem repeat sequences in the 3'-untranslated region of primate dopamine transporter genes that affects reporter gene expres-sion. Neurosci Lett 334: 206-210.
31. Kang AM, Palmatier MA, Kidd KK (1999). Global variation of a 40-bp VNTR in the 3'-untranslated region of the dopamine transporter gene (SLC6A3). Biol Psychiatry 46: 151-160.
32. Koob GF, Volkow ND (2010). Neurocircuitry of addiction. Neuropsychopharmacology 35: 217-238.
33. Kranzler HR, Van Kirk J (2001). Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis. Alcohol Clin Exp Res 25: 1335-1341.
34. Kringelbach ML, Rolls ET (2004). The functional neuroanatomy of the human orbitofrontal cortex: evidence from neuroimaging and neuropsychology. Prog Neurobiol 72: 341-372.
35. Le Merrer J, Becker JA, Befort K, Kieffer BL (2009). Reward processing by the opioid system in the brain. Physiol Rev 89: 1379-1412.
36. McGeary JE, Monti PM, Rohsenow DJ, Tidey J, Swift R, Miranda R Jr. (2006). Genetic moderators of naltrexone's effects on alcohol cue reactivity. Alcohol Clin Exp Res 30: 1288-1296.
37. Mill J, Asherson P, Browes C, D'Souza U, Craig I (2002). Expression of the dopamine transporter gene is regulated by the 3' UTR VNTR: Evidence from brain and lymphocytes using quantitative RT-PCR. Am J Med Genet 114: 975-979.
38. Miller GM, Madras BK (2002). Polymorphisms in the 3'-untran-slated region of human and monkey dopamine transporter genes affect reporter gene expression. Mol Psychiatry 7: 44-55.
39. Myrick H, Anton RF, Li X, Henderson S, Drobes D, Voronin K et al (2004). Differential brain activity in alcoholics and social drinkers to alcohol cues: relationship to craving. Neuropsycho-pharmacology 29: 393-402.
40. Myrick H, Anton RF, Li X, Henderson S, Randall PK, Voronin K (2008). Effect of naltrexone and ondansetron on alcohol cue-induced activation of the ventral striatum in alcohol-dependent people. Arch Gen Psychiatry 65: 466-475.
41. Myrick H, Li X, Randall PK, Henderson S, Voronin K, Anton RF (2010). The effect of aripiprazole on cue-induced brain activation and drinking parameters in alcoholics. J Clin Psychopharmacol 30: 365-372.
42. Nikolova YS, Ferrell RE, Manuck SB, Hariri AR (2011). Multilocus genetic profile for dopamine signaling predicts ventral striatum reactivity. Neuropsychopharmacology 36: 1940-1947.
43. O'Malley SS, Krishnan-Sarin S, Farren C, Sinha R, Kreek MJ (2002). Naltrexone decreases craving and alcohol self-administration in alcohol-dependent subjects and activates the hypothalamo-pituitary- adrenocortical axis. Psychopharmacology (Berl) 160: 19-29.
44. Oslin DW, Berrettini W, Kranzler HR, Pettinati H, Gelernter J, Volpicelli JR et al (2003). A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology 28: 1546-1552.
45. Pinsonneault JK, Han DD, Burdick KE, Kataki M, Bertolino A, Malhotra AK et al (2011). Dopamine transporter gene variant affecting expression in human brain is associated with bipolar disorder. Neuropsychopharmacology 36: 1644-1655.
46. Ramchandani VA, Umhau J, Pavon FJ, Ruiz-Velasco V, Margas W, Sun H et al (2011). A genetic determinant of the striatal dopamine response to alcohol in men. Mol Psychiatry 16: 809-817.
47. Ray LA, Barr CS, Blendy JA, Oslin D, Goldman D, Anton RF (2012a). The role of the Asn40Asp polymorphism of the mu opioid receptor gene (OPRM1) on alcoholism etiology and treatment: a critical review. Alcohol Clin Exp Res 36: 385-394.
48. Ray LA, Bujarski S, Chin PF, Miotto K (2012b). Pharmacogenetics of naltrexone in asian americans: a randomized placebo-controlled laboratory study. Neuropsychopharmacology 37: 445-455.
49. Ray LA, Hutchison KE (2004). A polymorphism of the mu-opioid receptor gene (OPRM1) and sensitivity to the effects of alcohol in humans. Alcohol Clin Exp Res 28: 1789-1795.
50. Ray LA, Hutchison KE (2007). Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response: a double-blind placebo-controlled study. Arch Gen Psychiatry 64: 1069-1077.
51. Rosner S, Hackl-Herrwerth A, Leucht S, Vecchi S, Srisurapanont M, Soyka M (2010). Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev CD001867.
52. Schacht JP, Anton RF, Myrick H (2012). Functional neuroimaging studies of alcohol cue reactivity: a quantitative meta-analysis and systematic review. Addict Biol (e-pub ahead of print).
53. Schacht JP, Anton RF, Randall PK, Li X, Henderson S, Myrick H (2011). Stability of fMRI striatal response to alcohol cues: A hierarchical linear modeling approach. NeuroImage 56: 61-68.
54. Schwandt ML, Lindell SG, Higley JD, Suomi SJ, Heilig M, Barr CS (2011). OPRM1 gene variation influences hypothalamic-pitui-tary-adrenal axis function in response to a variety of stressors in rhesus macaques. Psychoneuroendocrinology 36: 1303-1311.
55. Skinner HA, Allen BA (1982). Alcohol dependence syndrome: measurement and validation. J Abnorm Psychol 91: 199-209.
56. Smith SM, Jenkinson M, Woolrich MW, Beckmann CF, Behrens TE, Johansen-Berg H et al (2004). Advances in functional and structural MR image analysis and implementation as FSL. NeuroImage 23(Suppl 1): S208-S219.
57. Sobell LC, Sobell MB (1992). Timeline follow-back: a technique for assessing self-reported alcohol consumption. In: Allen JP, Litten RZ (eds). Measuring Alcohol Consumption: Psychosocial and Biochemical Methods. Humana Press: Totowa, NJ, pp 41-72.
58. Stritzke WG, Breiner MJ, Curtin JJ, Lang AR (2004). Assessment of substance cue reactivity: advances in reliability, specificity, and validity. Psychol Addict Behav 18: 148-159.
59. Sullivan JT, Sykora K, Schneiderman J, Naranjo CA, Sellers EM (1989). Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar). Br J Addict 84: 1353-1357.
60. Tidey JW, Monti PM, Rohsenow DJ, Gwaltney CJ, Miranda R Jr., McGeary JE et al (2008). Moderators of naltrexone's effects on drinking, urge, and alcohol effects in non-treatment-seeking heavy drinkers in the natural environment. Alcohol Clin Exp Res 32: 58-66.
61. VanNess SH, Owens MJ, Kilts CD (2005). The variable number of tandem repeats element in DAT1 regulates in vitro dopamine transporter density. BMC Genet 6: 55.
62. Weerts EM, Kim YK, Wand GS, Dannals RF, Lee JS, Frost JJ et al (2008). Differences in delta- and mu-opioid receptor blockade measured by positron emission tomography in naltrexone-treated recently abstinent alcohol-dependent subjects. Neurop-sychopharmacology 33: 653-665.
63. Weerts EM, McCaul ME, Kuwabara H, Yang X, Xu X, Dannals RF et al (2012). Influence of OPRM1 Asn40Asp variant (A118G) on [11C]carfentanil binding potential: preliminary findings in human subjects. Int J Neuropsychopharmacol 1-7.
64. Yoshimoto K, McBride WJ, Lumeng L, Li TK (1992). Ethanol enhances the release of dopamine and serotonin in the nucleus accumbens of HAD and LAD lines of rats. Alcohol Clin Exp Res 16: 781-785.
65. Zhang Y, Wang D, Johnson AD, Papp AC, Sadee W (2005). Allelic expression imbalance of human mu opioid receptor (OPRM1) caused by variant A118G. J Biol Chem 280: 32618-32624.